Septerna, Inc. (SEPN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Septerna reported revenue of $46.0M, up 4174.5% from $1.1M the year before. Net income was -$48.9M (a -106.4% net margin), or -$1.10 per diluted share. Operating margin was -148.6%. Operating activities generated $110.2M of cash, leaving $109.7M of free cash flow. At fiscal year end, Septerna held $596.2M in total assets against $214.3M in total liabilities, including $120.7M of cash and equivalents.
Open the full interactive Septerna financials → Quarterly statements, key ratios, valuation history and price charts.
Septerna Key Stats
| Share Price | $36.42 |
|---|---|
| Market Cap | $1.64B |
| 52-Week Range | $18.10 – $48.19 |
| Shares Outstanding | 45.0 million (basic, 2026 Q2) |
Septerna Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $1.1M | $46.0M |
| Operating Income | -$80.8M | -$68.3M |
| Pre-Tax Income | -$72.3M | -$48.9M |
| Income Tax | -$498,000 | $12,000 |
| Net Income | -$71.8M | -$48.9M |
| Diluted EPS | -$7.26 | -$1.10 |
Septerna Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $21.5M | $24.1M | $26.5M | $26.7M |
| Net Income | $8.2M | -$10.7M | -$8.6M | -$13.0M |
| Diluted EPS | $0.18 | -$0.24 | -$0.19 | -$0.29 |
Septerna Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $238.2M | $120.7M |
| Current Assets | $356.8M | $411.0M |
| Total Assets | $456.6M | $596.2M |
| Current Liabilities | $12.8M | $86.9M |
| Total Liabilities | $36.5M | $214.3M |
| Shareholders' Equity | $420.0M | $381.9M |
Septerna Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$67.5M | $110.2M |
| Cash From Investing | -$160.6M | -$229.4M |
| Cash From Financing | $377.8M | $1.7M |
| Free Cash Flow | -$69.6M | $109.7M |
Figures from Septerna's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Septerna financials page for every line item.
Septerna Company Profile
| Ticker | SEPN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001984086 |
Frequently Asked Questions
What was Septerna's revenue in fiscal 2025?
Septerna (SEPN) reported revenue of $46.0M for fiscal 2025.
What was Septerna's net income in fiscal 2025?
Septerna reported net income of -$48.9M for fiscal 2025.
What was Septerna's earnings per share (EPS) in fiscal 2025?
Septerna's diluted EPS was -$1.10 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Septerna generate in fiscal 2025?
Septerna generated $109.7M of free cash flow in fiscal 2025.
What was Septerna's revenue last quarter?
In its most recent reported quarter (2026 Q2), Septerna reported revenue of $26.7M.
How many shares of Septerna are outstanding?
Septerna reported a weighted average of 45.0 million basic shares outstanding in 2026 Q2.
What is Septerna's market cap?
Based on its latest closing price, Septerna (SEPN) has a market capitalization of about $1.64B.
When does Septerna's fiscal year end?
Septerna's fiscal year end, as registered with the SEC, is December 31.
Where is Septerna headquartered?
Septerna lists its business address in South San Francisco, California in its SEC filings.